SCYNEXIS, Inc. (LON: 0L49)

Market Cap	32.96M
Revenue (ttm)	6.39M
Net Income (ttm)	-27.19M
Shares Out	n/a
EPS (ttm)	-0.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	203
Average Volume	2,890
Open	1.120
Previous Close	1.122
Day's Range	1.100 - 1.130
52-Week Range	0.796 - 2.481
Beta	n/a
RSI	42.78
Earnings Date	Mar 28, 2025

About SCYNEXIS

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company’s lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The co...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 29
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0L49

Financial Performance

Financial numbers in USD